NASDAQ: PMCBPharmacyte Biotech Inc Stock
$1.13-0.06 (-5.04%)
Updated Apr 21, 2025
PMCB Price
$1.13
Fair Value Price
N/A
Market Cap
$7.76M
52 Week Low
$1.03
52 Week High
$2.42
P/E
1.53x
P/B
0.19x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
$20.25M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.09
Operating Cash Flow
-$2M
Beta
0.44
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
PMCB Overview
PharmaCyte Biotech, Inc. is developing cellular therapies for cancer and diabetes in the U.S. Its therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology. Formerly Nuvilex, Inc., PharmaCyte Biotech was incorporated in 1996 and is headquartered in Laguna Hills, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PMCB's potential to beat the market
- PMCB doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
PMCB
RankedUnranked of 462
RankedUnranked of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.55 | A | |
| $7.66 | A | |
| $22.02 | A |
Be the first to know about important PMCB news, forecast changes, insider trades & much more!
PMCB News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PMCB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PMCB is good value based on its earnings relative to its share price (1.53x), compared to the US market average (27.14x)
P/E vs Market Valuation
PMCB is good value based on its earnings relative to its share price (1.53x), compared to the US Biotechnology industry average (-184.27x)
P/E vs Industry Valuation
PMCB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more PMCB due diligence checks available for Premium users.
Valuation
PMCB fair value
Fair Value of PMCB stock based on Discounted Cash Flow (DCF)
Price
$1.13
Fair Value
$5.24
Undervalued by
78.42%
PMCB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
1.53x
Industry
-184.27x
Market
27.14x
PMCB is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
PMCB is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
PMCB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.19x
Industry
4.04x
PMCB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PMCB's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.0M
Profit Margin
0%
PMCB's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$43.8M
Liabilities
$3.6M
Debt to equity
0.09
PMCB's short-term assets ($16.96M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PMCB's short-term assets ($16.96M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PMCB's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PMCB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$509.9k
Investing
$0.0
Financing
-$3.9M
PMCB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PMCB vs Biotech Stocks
Pharmacyte Biotech Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.